TY  - JOUR
AU  - Feng Xue-Sheng
AU  - Zheng Xiu-Juan
AU  - Si Qiu-Sheng
AU  - Lin Yun-Lu
AU  - Chang Yuan
AU  - Fan Pei-Fang
AU  - Yu Jian-Liang
AU  - Zhang Shu-Ren
AU  - Liu Xin-Yuan
PY  - 2016
TI  - Antitumor effects of new-type recombinant interleukin-2
JF  - Acta Pharmacologica Sinica; Vol 13, No 5 (September 1992): Acta Pharmacologica Sinica
Y2  - 2016
KW  - 
N2  - Two new human recombinant interleukin-2 (rIL-2), 125-Ser-rIL-2, and 125-Ala-rIL-2, were generated by protein engineering technique. Both of them maintained the proliferation of natural killer (NK) cells, CTLL-2 cells and their long-term propagations. The mutated new rIL-2 also enhanced the bioactivity of NK cells and the cytotoxicity of tumor-infiltrating lymphocytes (TIL) against the target tumor cells. The above results were all compared with that of the native rIL-2 and a similarity between them was found, which indicates that new type rIL-2 could be used for adoptive immunotherapy of malignant diseases.
UR  - http://www.chinaphar.com/article/view/6272